Wang Yu-Chieh, Li Jian-Ri, Chen Chuan-Shu, Wang Shian-Shiang, Yang Cheng-Kuang, Chiu Kun-Yuan, Hsu Chiann-Yi
Department of Medical Education, Taichung Veterans General Hospital, Taichung, Taiwan.
School of Medicine, Chung-Shan Medical University, Taichung, Taiwan.
Ann Surg Oncol. 2025 Feb;32(2):1354-1363. doi: 10.1245/s10434-024-16523-y. Epub 2024 Nov 16.
This study investigated the utilization of kidney-sparing surgery (KSS) as an alternative option to radical nephroureterectomy (RNU) in managing upper urinary tract urothelial carcinoma (UTUC) patients.
Our study aimed to compare the functional outcomes and oncological outcomes between KSS and RNU.
We retrospectively analyzed 252 patients with UTUC without clinical node positivity or metastasis who had been treated with either RNU or KSS. We collected information on each patient, including clinicopathological factors, renal function variations, and oncological outcomes. Hemodialysis-free survival (HDFS), stage 4 chronic kidney disease (CKD4) progression-free survival (PFS), recurrence-free survival (RFS), and overall survival (OS) were assessed using inverse probability of treatment weighting (IPTW)-weighted Kaplan-Meier analysis. The hazard ratio for oncological and functional outcomes of KSS was analyzed using the Cox proportional hazards model.
The OS at 8 years was 77.06% (RNU) and 70.59% (KSS) and did not significantly differ between the two groups (p = 0.691), although the KSS group experienced a higher recurrence rate. Functional outcomes indicated no significant difference in postoperative renal function at 1 year; however, KSS was associated with better preservation of renal function (23.44% vs. 28.23%), albeit not statistically significant (p = 0.055). Kaplan-Meier analysis revealed no significant disparities in CKD4 PFS between the KSS and RNU groups involved in the study (p = 0.089), although the KSS group displayed poorer HDFS than the RNU group (p = 0.001).
KSS had no compromising survival outcomes when compared with RNU, not only in low-risk patients but also in high-risk patients with a normal contralateral kidney. The efficacy of renal function preservation was presented in this study, however the results were below our expectations.
本研究探讨了在治疗上尿路尿路上皮癌(UTUC)患者时,保留肾手术(KSS)作为根治性肾输尿管切除术(RNU)替代方案的应用情况。
我们的研究旨在比较KSS和RNU之间的功能结局和肿瘤学结局。
我们回顾性分析了252例无临床淋巴结阳性或转移的UTUC患者,这些患者接受了RNU或KSS治疗。我们收集了每位患者的信息,包括临床病理因素、肾功能变化和肿瘤学结局。使用治疗权重逆概率(IPTW)加权的Kaplan-Meier分析评估无血液透析生存期(HDFS)、4期慢性肾脏病(CKD4)无进展生存期(PFS)、无复发生存期(RFS)和总生存期(OS)。使用Cox比例风险模型分析KSS的肿瘤学和功能结局的风险比。
8年时的总生存期分别为77.06%(RNU)和70.59%(KSS),两组之间无显著差异(p = 0.691),尽管KSS组的复发率较高。功能结局表明,术后1年肾功能无显著差异;然而,KSS与更好地保留肾功能相关(23.44%对28.23%),尽管无统计学意义(p = 0.055)。Kaplan-Meier分析显示,参与研究的KSS组和RNU组在CKD4无进展生存期方面无显著差异(p = 0.089),尽管KSS组的无血液透析生存期比RNU组差(p = 0.001)。
与RNU相比,KSS在生存结局方面没有妥协,不仅在低风险患者中如此,在对侧肾脏正常的高风险患者中也是如此。本研究显示了保留肾功能的疗效,然而结果低于我们的预期。